X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (54) 54
index medicus (50) 50
aged (45) 45
cardiac & cardiovascular systems (45) 45
male (45) 45
female (43) 43
atrial fibrillation (38) 38
stroke - prevention & control (35) 35
rivaroxaban (34) 34
treatment outcome (33) 33
atrial fibrillation - drug therapy (32) 32
stroke (32) 32
warfarin (32) 32
atrial fibrillation - complications (27) 27
double-blind method (26) 26
warfarin - administration & dosage (24) 24
abridged index medicus (23) 23
middle aged (23) 23
prevention (23) 23
anticoagulants (21) 21
anticoagulants - administration & dosage (21) 21
risk factors (21) 21
stroke - etiology (21) 21
anticoagulants - therapeutic use (19) 19
embolism - prevention & control (19) 19
warfarin - adverse effects (19) 19
anticoagulants - adverse effects (18) 18
risk (16) 16
warfarin - therapeutic use (16) 16
therapy (15) 15
cardiac arrhythmia (14) 14
heart attacks (14) 14
hemorrhage - chemically induced (14) 14
administration, oral (13) 13
aged, 80 and over (13) 13
management (13) 13
morpholines - administration & dosage (13) 13
thiophenes - administration & dosage (13) 13
anticoagulation (12) 12
care and treatment (12) 12
peripheral vascular disease (12) 12
clinical trials (11) 11
embolism (11) 11
factor xa inhibitors - administration & dosage (11) 11
morpholines - adverse effects (11) 11
morpholines - therapeutic use (11) 11
rivaroxaban - administration & dosage (11) 11
thiophenes - adverse effects (11) 11
vitamin k - antagonists & inhibitors (11) 11
dabigatran (10) 10
drug therapy (10) 10
embolism - etiology (10) 10
mortality (10) 10
outcomes (10) 10
stroke - epidemiology (10) 10
thiophenes - therapeutic use (10) 10
atrial fibrillation - diagnosis (9) 9
blood coagulation - drug effects (9) 9
comparative analysis (9) 9
embolisms (9) 9
fibrillation (9) 9
time factors (9) 9
atrial fibrillation - blood (8) 8
atrial fibrillation - mortality (8) 8
bleeding (8) 8
cardiovascular (8) 8
drug administration schedule (8) 8
follow-up studies (8) 8
original research (8) 8
rivaroxaban - adverse effects (8) 8
stroke prevention (8) 8
atrial-fibrillation (7) 7
factor xa inhibitors (7) 7
factor xa inhibitors - adverse effects (7) 7
factor xa inhibitors - therapeutic use (7) 7
hemorrhage (7) 7
international normalized ratio (7) 7
patients (7) 7
rivaroxaban - therapeutic use (7) 7
singers (7) 7
arrhythmia and electrophysiology (6) 6
atrial fibrillation - epidemiology (6) 6
cardiovascular disease (6) 6
dosage and administration (6) 6
drug monitoring - methods (6) 6
efficacy (6) 6
hypertension (6) 6
medicine, general & internal (6) 6
molecular-weight heparin (6) 6
patient outcomes (6) 6
predictive value of tests (6) 6
proportional hazards models (6) 6
retrospective studies (6) 6
risk-factors (6) 6
safety (6) 6
adult (5) 5
analysis (5) 5
aspirin (5) 5
cardiology and cardiovascular medicine (5) 5
clinical outcomes (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2011, Volume 365, Issue 10, pp. 883 - 891
In this trial, 14,264 patients with atrial fibrillation were randomly assigned to receive either rivaroxaban or warfarin. In a per-protocol, as-treated... 
NON-INFERIORITY | ENOXAPARIN | MEDICINE, GENERAL & INTERNAL | DABIGATRAN | STROKE PREVENTION | PHARMACOKINETICS | EFFICACY | ANTITHROMBOTIC THERAPY | PHARMACODYNAMICS | THROMBOPROPHYLAXIS | ANTICOAGULATION | Thiophenes - therapeutic use | Thiophenes - adverse effects | Humans | Middle Aged | Warfarin - adverse effects | Male | Thiophenes - administration & dosage | Warfarin - administration & dosage | Warfarin - therapeutic use | Rivaroxaban | Aged, 80 and over | Female | Stroke - epidemiology | Embolism - epidemiology | Morpholines - adverse effects | Morpholines - therapeutic use | Stroke - prevention & control | Embolism - prevention & control | Double-Blind Method | Administration, Oral | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Intention to Treat Analysis | Aged | Hemorrhage - chemically induced | Stroke (Disease) | Warfarin | Atrial fibrillation | Patient outcomes | Dosage and administration | Drug therapy | Comparative analysis | Risk factors | Fees & charges | Cardiac arrhythmia | Stroke | Heart attacks | Research & development--R&D | Embolisms | Equity | Equity stake | Hemorrhage | Bleeding | Embolism | Studies | Prevention | Fibrillation | Motivation | Ischemia | Thromboembolism | Drug dosages | Pharmaceuticals | Anticoagulants | Morpholines | Life Sciences | Thiophenes | Atrial Fibrillation
Journal Article
CIRCULATION, ISSN 0009-7322, 01/2013, Volume 127, Issue 2, pp. 224 - 224
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 07/2014, Volume 130, Issue 2, pp. 138 - 146
Journal Article